Dr. Ronald Sokol, MD

NPI: 1578647202
Total Payments
$23,787
2024 Payments
$8,903
Companies
7
Transactions
23

Payment Breakdown by Category

Consulting$16,398 (68.9%)
Travel$6,071 (25.5%)
Food & Beverage$1,080 (4.5%)
Other$215.52 (0.9%)
Education$23.11 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $16,398 8 68.9%
Travel and Lodging $6,071 6 25.5%
Food and Beverage $1,080 7 4.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $215.52 1 0.9%
Education $23.11 1 0.1%

Top Paying Companies

Company Total Records Latest Year
Mirum Pharmaceuticals, Inc. $15,564 16 $0 (2024)
Ipsen Innovation $2,490 1 $0 (2024)
Mallinckrodt Hospital Products Inc. $2,413 2 $0 (2024)
ALBIREO PHARMA, INC. $1,950 1 $0 (2022)
Astellas Pharma Inc $1,200 1 $0 (2022)
Ipsen Biopharmaceuticals, Inc $147.61 1 $0 (2023)
Travere Therapeutics, Inc. $23.11 1 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $8,903 5 Mirum Pharmaceuticals, Inc. ($4,000)
2023 $8,477 10 Mirum Pharmaceuticals, Inc. ($8,329)
2022 $6,407 8 Mirum Pharmaceuticals, Inc. ($3,234)

All Payment Transactions

23 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/04/2024 Mallinckrodt Hospital Products Inc. TERLIVAZ (Drug) Consulting Fee Cash or cash equivalent $2,370.00 General
Category: CRITICAL CARE
06/07/2024 Ipsen Innovation IQIRVO (Drug) Consulting Fee Cash or cash equivalent $2,490.00 General
Category: Rare Disease
04/06/2024 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Consulting Fee Cash or cash equivalent $1,200.00 General
Category: Alagille syndrome
04/06/2024 Mallinckrodt Hospital Products Inc. TERLIVAZ (Drug) Food and Beverage In-kind items and services $42.68 General
Category: CRITICAL CARE
03/27/2024 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Consulting Fee Cash or cash equivalent $2,800.00 General
Category: Alagille syndrome
11/13/2023 Ipsen Biopharmaceuticals, Inc Food and Beverage In-kind items and services $147.61 General
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Travel and Lodging Cash or cash equivalent $3,250.00 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Consulting Fee Cash or cash equivalent $2,275.00 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Travel and Lodging Cash or cash equivalent $1,352.37 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Food and Beverage Cash or cash equivalent $654.94 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Travel and Lodging Cash or cash equivalent $523.23 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Travel and Lodging Cash or cash equivalent $135.02 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Food and Beverage Cash or cash equivalent $55.48 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Food and Beverage Cash or cash equivalent $54.46 General
Category: Alagille syndrome
07/22/2023 Mirum Pharmaceuticals, Inc. Livmarli (Drug) Food and Beverage Cash or cash equivalent $28.87 General
Category: Alagille syndrome
12/26/2022 Mirum Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $2,112.50 General
09/19/2022 Travere Therapeutics, Inc. Cholbam (Drug) Education In-kind items and services $23.11 General
Category: Hepatology
09/16/2022 Astellas Pharma Inc Consulting Fee Cash or cash equivalent $1,200.00 General
08/01/2022 Mirum Pharmaceuticals, Inc. Travel and Lodging Cash or cash equivalent $566.96 General
08/01/2022 Mirum Pharmaceuticals, Inc. Travel and Lodging Cash or cash equivalent $243.54 General
08/01/2022 Mirum Pharmaceuticals, Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $215.52 General
08/01/2022 Mirum Pharmaceuticals, Inc. Food and Beverage Cash or cash equivalent $95.73 General
05/23/2022 ALBIREO PHARMA, INC. Bylvay (Drug) Consulting Fee Cash or cash equivalent $1,950.00 General
Category: Gastroenterology

About Dr. Ronald Sokol, MD

Dr. Ronald Sokol, MD is a Pediatric Gastroenterology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578647202.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Sokol, MD has received a total of $23,787 in payments from pharmaceutical and medical device companies, with $8,903 received in 2024. These payments were reported across 23 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($16,398).

Practice Information

  • Specialty Pediatric Gastroenterology
  • Location Aurora, CO
  • Active Since 10/25/2006
  • Last Updated 07/23/2012
  • Taxonomy Code 2080P0206X
  • Entity Type Individual
  • NPI Number 1578647202

Products in Payments

  • Livmarli (Drug) $12,329
  • IQIRVO (Drug) $2,490
  • TERLIVAZ (Drug) $2,413
  • Bylvay (Drug) $1,950
  • Cholbam (Drug) $23.11

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Gastroenterology Doctors in Aurora